Patents Assigned to Cambridge Antibody Technology Limited
  • Patent number: 5858657
    Abstract: The invention provides methods and kits for producing specific binding pairs (sbp) members. Populations of polypeptide chain components of sbp members are combined to form libraries of sbps displayed by secreted replicable genetic display packages (rgdp). At least one of the polypeptide chains is expressed as a fusion with a component of an rgdp which thereby displays that polypeptide chain at the surface of rgdp. At least one population of polypeptide chains is expressed from nucleic acid which is capable of being packaged using a component of an rgdp, whereby the genetic material of rgdps produced encodes a polypeptide chain. The methods enable production of libraries of multimeric sbp members from a very large number of possible combinations. In one embodiment of the invention a method employs "chain shuffling" in the production of sbp members of desired specificity for a counterpart sbp member. Selection procedures are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 12, 1999
    Assignees: Medical Research Council, Cambridge Antibody Technology Limited
    Inventors: Gregory Paul Winter, Kevin Stuart Johnson, Andrew David Griffiths, Andrew John Hammond Smith
  • Patent number: 5837242
    Abstract: Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin light chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form antigen binding multimers, such as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed, along with many utilities.
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: November 17, 1998
    Assignees: Medical Research Council, Cambridge Antibody Technology Limited
    Inventors: Kaspar-Philipp Holliger, Andrew David Griffiths, Hendricus Renerus Jacobus Matheus Hoogenboom, Magnus Malmqvist, James David Marks, Brian Timothy McGuinness, Anthony Richard Pope, Terence Derek Prospero, Gregory Paul Winter
  • Patent number: 5733743
    Abstract: Methods, recombinant host cells and kits are disclosed for the production of members of specific binding pairs (sbp), e.g. antibodies, using display on the surface of secreted replicable genetic display packages (rgdps), e.g. filamentous phage. To produce a library of great diversity, recombination occurs between first and second vectors comprising nucleic acid encoding first and second polypeptide chains of sbp members respectively, thereby producing recombinant vectors each encoding both a first and a second polypeptide chain component of an sbp member. The recombination may take place in vitro or intracellularly and may be site-specific, e.g. involving use of the loxP sequence and mutants thereof. Recombination may take place after prior screening or selecting for rgdps displaying sbp members which bind complementary sbp member of interest.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: March 31, 1998
    Assignees: Cambridge Antibody Technology Limited, Medical Research Council
    Inventors: Kevin Stuart Johnson, Gregory Paul Winter, Andrew David Griffiths, Andrew John Hammond Smith, Peter Michael Waterhouse
  • Patent number: 5565332
    Abstract: Methods are disclosed which may be used for the production of antibodies, or antibody fragments, which have the same binding specificity as a parent antibody but which have increased human characteristics. Humanized antibodies may be obtained by chain shuffling, perhaps using phage display technology. In one embodiment, a polypeptide comprising a heavy or light chain variable domain of a non-human antibody specific for an antigen of interest is combined with a repertoire of human complementary (light or heavy) chain variable domains. Hybrid pairings which are specific for the antigen of interest are selected. Human chains from the selected pairings may then be combined with a repertoire of human complementary variable domains (heavy or light) and humanized antibody polypeptide dimers can then be selected for binding specificity for antigen. The methods may be combined with CDR-imprinting.
    Type: Grant
    Filed: June 24, 1994
    Date of Patent: October 15, 1996
    Assignees: Medical Research Council, Cambridge Antibody Technology Limited
    Inventors: Hendricus R. J. M. Hoogenboom, Michael Baier, Laurent S. A. T. Jespers, Gregory P. Winter